Investigating the role of the gastrointestinal microbiome in response to immune checkpoint inhibitors (ICIs) among patients (pts) with metastatic renal cell carcinoma (mRCC).

Anika Agarwal(Duke Medical Center), Tian Zhang(Duke Medical Center), Raphael H. Valdivia(Duke University), Andrew J. Armstrong(Duke University), Holly K. Dressman(Duke University), Marco Reyes-Martinez(Duke University), Jennifer L. Modliszewski(Duke University), Daniella Runyambo(Duke Medical Center), Lauren Davey(Duke University), David L. Corcoran(NHS Greater Glasgow and Clyde), Daniel J. George(Duke University)
Journal of Clinical Oncology
February 19, 2020
10.1200/jco.2020.38.6_suppl.730
Cited by 8

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
|Molecular Cancer Research|2011|650
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
|Journal of Clinical Oncology|2019|364